ArticleInternational cancer conference journal2025
Primary ALK-negative ALCL of the small intestine: a rare case report with review of literature.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ALK-negative primary anaplastic large cell lymphoma (ALCL) of the small intestine is exceptionally rare and presents significant diagnostic and therapeutic challenges. Characterized by large-sized neoplastic lymphoid cells with scant cytoplasm and pleomorphic nuclei, its clinical presentation is often nonspecific, mimicking infections or inflammatory disorders. We present a rare case of ALK-negative primary ALCL of the small intestine in a 35-year-old male who presented with fever, abdominal pain, and significant weight loss. This case highlights the need for heightened clinical suspicion, a comprehensive histopathological and immunophenotypic approach, and optimal management strategies for this aggressive entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.